$ALLO

Allogene (NASDAQ: ALLO) details 2025 loss, pipeline data milestones and cash runway

Allogene Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighting a net loss of $190.9 million or $0.87 per share for the year. The company provided updates on key pipeline milestones, including an interim futility analysis for the ALPHA3 trial of cema-cel in April 2026 and proof-of-concept data for the RESOLUTION trial of ALLO-329 in autoimmune disease in June 2026. Allogene ended 2025 with $258.3 million in cash, cash equivalents, and investments, extending its cash runway into the first quarter of 2028.

Original reporting
Published Mar 13, 2026, 3:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 13, 2026, 4:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Allogene (NASDAQ: ALLO) details 2025 loss, pipeline data milestones and cash runway — source image
Decision brief

The 30-second read

$ALLONeutralLow
01

Why it matters

Upcoming trial data releases are critical; positive results could boost stock, while setbacks may lead to declines.

02

Market read

High relevance for biotech investors; moderate relevance for broader markets.

03

What to watch

Potential regulatory changes or partnership announcements could significantly alter the outlook.

Timing: medium-term (next 3-6 months)

Background

Allogene Therapeutics is advancing its CAR-T cell therapies with key clinical milestones scheduled for 2026.

Company-level read

Ticker impact

$ALLONeutralMedium confidence
Context

Primary focus due to recent financial results and pipeline updates.

Expected impact

Potential for moderate positive movement around milestone dates; however, overall impact remains uncertain due to financial losses.

Evidence & confidence

Financial losses and upcoming clinical milestones create mixed signals; market reaction will depend on trial outcomes and investor sentiment.

Market effects

Biotech sector may experience volatility based on clinical trial outcomes and pipeline progress.

Limited; primarily affects US biotech stocks.

Low; company-specific news with minimal immediate global impact.

Counterpoint

Positive trial results could lead to a sharp rally, making this an opportunity for swing traders.

Key entities

  • Allogene Therapeutics

    Biotech company specializing in allogeneic CAR-T cell therapies.

  • ALPHA3 trial

    Interim futility analysis scheduled for April 2026.

  • RESOLUTION trial

    Proof-of-concept data expected in June 2026.

Related articles

$BKRMed

Baker Hughes extends long-term service deal for Nigeria LNG Train 7

Baker Hughes said it won a 13-year lifecycle services deal with Nigeria LNG for turbomachinery at NLNG’s Train 7 expansion on Bonny Island. The scope covers heavy-duty gas turbines, centrifugal compressors, remote monitoring via Baker Hughes’ digital platform, and local support. Train 7 is expected to raise capacity from 22 to 30 MMtpa.

$BKRMed

Baker Hughes wins subsea systems contract for Angola's Greater PAJ field

Baker Hughes said it won a contract from Azule Energy to supply subsea production systems for the Greater PAJ ultra-deepwater project offshore Angola. Scope includes horizontal subsea trees, control modules, workover control systems and related equipment plus installation and support. Greater PAJ is expected to start producing in 2029 via an FPSO processing up to 95,000 bpd, with deliveries starting in 2027.

$WENMed

57-year-old Burger chain closed 28 restaurants, 100s more coming

Wendy’s (WEN) said it closed 28 restaurants and expects to close 5% to 6% of U.S. units (about 289 to 358) in 1H 2026, with possible additional selective closures. The company reported 2Q FY2026 systemwide sales down 6.5% YoY, U.S. systemwide down 8.2%, and U.S. same-restaurant sales down 7%. Wendy’s launched a turnaround plan and withdrew its 2026 outlook.

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.